Journal Scans
Lymphoma Cell VEGFR2 Expression Detected by Immunohistochemistry Predicts Poor Overall Survival in Diffuse Large B Cell Lymphoma Treated With Immunochemotherapy (R-CHOP)
VEGF Association With R-CHOP in DLBCL
D Gratzinger, R Advani, S Zhao, N Talreja, R Tibshirani, R Shyam, S Horning, L Sehn, P Farinha, J Briones, I Lossos, R Gascoyne, Y Natkunam
20090911
2009 Oct 11
Br J Haematol
Lymphoma Cell VEGFR2 Expression Detected by Immunohistochemistry Predicts Poor Overall Survival in Diffuse Large B Cell Lymphoma Treated With Immunochemotherapy (R-CHOP)
Br J Haematol. 2009 Oct 11;148(2):235-244, D Gratzinger, R Advani, S Zhao, N Talreja, R Tibshirani, R Shyam, S Horning, L Sehn, P Farinha, J Briones, I Lossos, R Gascoyne, Y Natkunam
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
The survival of patients with diffuse large B cell lymphoma (DLBCL) has been significantly improved by the use of combined immunochemotherapy with anti-CD20 recombinant antibody and anthracycline-based chemotherapy. Prognostic factors in this disease thus need to be reevaluated. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been found to be expressed in cell lines of various hematolymphoid malignancies. In addition, VEGF, VEGFR1, and VEGFR2 are expressed in DLBCL specimens....
